Communiqués CanSino Biologics Inc.

Actions

6185

CNE100003F01

Produits pharmaceutiques

Temps Différé Hong Kong S.E. 03:39:32 17/08/2026			Varia. 5j.	Varia. 1 janv.
24,86 ^HKD	+0,65%		+1,80%	-28,64%

19/07	CanSino Biologics Inc. : la demande de nouveau médicament pour le Menhycia acceptée	CI
16/07	Les laboratoires chinois aux ambitions mondiales peinent à recruter pour leur expansion internationale	RE

Communiqués

16/08	CanSinoBIO's NDA for Td5cp Adolescent and Adult Accepted, Further Strengthening Its Diversified Vaccine Pipeline	AQ
16/08	CanSino Biologics : CanSinoBIO's Td5cp Vaccine for Adolescents and Adults NDA Accepted by China's NMPA	PU
21/07	CanSino Biologics : CanSinoBIO Signs PCV13i LOI with Pakistani Partner to Expand Vaccine Collaboration in South Asia	PU
19/07	CanSino Biologics : CanSinoBIO's Menhycia® Application Accepted by China's NMPA for Expanded Use in Population Aged 3 Months to 17 Years	PU
25/06	CanSino Biologics : CanSinoBIO's MCV4 Receives Registration Approval in Argentina, Expanding Global Reach	PU
10/06	CanSino Biologics : CanSinoBIO Holds 2025 Annual General Meeting of Shareholders	PU
25/05	CanSino Biologics : CanSinoBIO Advances Pneumococcal Disease Prevention Strategy with Initiation of Phase I/II Trial for PCV24	PU
10/04	CanSino Biologics : Breaking News \| CanSinoBIO's Next-Generation Three-Component DTcP Vaccine Tripecia® Officially Approved	PU
25/02	CanSinoBIO's Menhycia (R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential	AQ
24/02	CanSino Biologics : Breaking News \| CanSino Biologics' Menhycia® (MCV4) Expands Age Indication to Include individuals up to age 6, Enhancing Meningococcal Prevention for School-aged children	PU
05/02	CanSino Biologics : CanSinoBIO Shares Global Practices in Innovative Vaccines at the 2026 World Governments Summit	PU
05/01	CanSino Biologics : CanSinoBIO Advances Pneumococcal Vaccine Portfolio as PCV24 Receives Clinical Trial Approval	PU
13/11	CanSino Biologics : CanSinoBIO Takes Next Step in Global TB Vaccine Research with Inhaled Vaccine Phase I Trial in Indonesia	PU
10/11	CanSino Biologics : CanSinoBIO Shanghai and PanRu Biotech Sign Licensing Agreement to Expand Applications of Three-Component LNP Delivery System	PU
08/11	Implementing International Cooperation and Regulatory Exchange: Tianjin Medical Products Administration and Indonesia’s BPOM Meet at CanSinoBIO	PU
16/10/25	CanSino Biologics : Scientific Insight Inspiring Innovation for a Healthier Future ——CanSinoBIO Convenes 2025 Annual Scientific Advisory Board Meeting	PU
29/09/25	CanSino Biologics : CanSinoBIO Expands Innovative Vaccine Impact with Domestic Launch of iPneucia® (PCV13i) and International Shipment of Menhycia®(MCV4)	PU
21/08/25	Bloomberg \| CanSinoBIO’s Xuefeng Yu: Leveraging High-Quality Innovation to Unlock New Growth Opportunities in the Vaccine Industry	PU
21/08/25	Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle	AQ
16/07/25	CanSino Biologics : CanSinoBIO's Innovative Recombinant Poliomyelitis Vaccine Obtains Clinical Trial Approval in China	PU
20/06/25	CanSinoBIO Launches Pneumococcal Vaccine: An Innovative Choice to Safeguard Children's Health	AQ
20/06/25	CanSino Biologics : CanSinoBIO Obtained NDA Approval for its 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine iPneucia®	PU
16/05/25	CanSino Biologics : CanSinoBIO Obtained Approval for Clinical Trials on Inhaled TB Vaccine in Indonesia	PU
26/03/25	CanSino Biologics : SPIMACO and CanSinoBIO Sign an Agreement to Localise and Market the MCV4 Vaccine in Saudi Arabia and MENA	PU
25/03/25	Revenue Soars with 137% Year-on-Year Growth, Multiple Products Poised for Launch, CanSinoBIO's Growth Momentum Strong	AQ